Review for 10.1186/s12876-020-01196-0 (2020)

Reviewer’s report
Title: Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors
for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study
Version: 0 Date: 27 Dec 2019
Reviewer: . Shalimar
Reviewer's report:
Charatcharoenwitthaya et al., in this multicenter study from Thailand, have reported results of DAA
therapy on CHC patients. The results are in concurrence with those reported from real-world studies
from other parts of the world.
1) The management of patients was based on the physician's choice of use of oral DAA combinations.
The major guidelines recommend different DAA combinations for genotype 1 and 3. Even the reported
results of outcomes of DAA combinations are different in genotype 1 and 3.
2) The authors used different duration of HCV regimens and ± Ribavirin. From the results of the
present study can the authors interpret the utility of Ribavirin and also the optimal duration of therapy
in different clinical phenotypes of HCV?
3) What were the outcomes (SVR12) among HCC patients as compared to the rest of the cirrhosis
patients without HCC?
4) The authors have compared their results with clinical trials that have their own limitations and are
different from real-world scenarios. There are real-world studies published in the literature (PMID:
29377464 and 29193226) which have highlighted the DAA outcomes. Consider adding more real-
world studies in the introduction and discussion section of the manuscript. 
5) Grammatical errors need correction.
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes
Are you able to assess any statistics in the manuscript or would you recommend an
additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further
assessment in your comments to the editors.
I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:
Needs some language corrections before being published
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:
1. Have you in the past five years received reimbursements, fees, funding, or salary from an
organisation that may in any way gain or lose financially from the publication of this
manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose
financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the
manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds
or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below.
If your reply is yes to any, please give details below.
none
I agree to the open peer review policy of the journal. I understand that my name will be included
on my report to the authors and, if the manuscript is accepted for publication, my named report
including any attachments I upload will be posted on the website along with the authors'
responses. I agree for my report to be made available under an Open Access Creative Commons
CC-BY license (http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments
which I do not wish to be included in my named report can be included as confidential comments
to the editors, which will not be published.
I agree to the open peer review policy of the journal